The impact of COVID‐19 on autism research: A cross‐sectional analysis of discontinued or suspended clinical trials

Due to uncertainties associated with the COVID‐19 public health crisis, several clinical trials had to be withdrawn or postponed. Our investigation aimed to assess the rate of discontinuation of clinical trials focusing on Autism Spectrum Disorder. Of the 197 registered trials included in our system...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Autism research 2022-08, Vol.15 (8), p.1560-1564
Hauptverfasser: Neale, Monika, Landers, Elizabeth, Sajjadi, Nicholas B., Mazur‐Mosiewicz, Anya, Hartwell, Micah
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1564
container_issue 8
container_start_page 1560
container_title Autism research
container_volume 15
creator Neale, Monika
Landers, Elizabeth
Sajjadi, Nicholas B.
Mazur‐Mosiewicz, Anya
Hartwell, Micah
description Due to uncertainties associated with the COVID‐19 public health crisis, several clinical trials had to be withdrawn or postponed. Our investigation aimed to assess the rate of discontinuation of clinical trials focusing on Autism Spectrum Disorder. Of the 197 registered trials included in our systematic review, 15 (7.6%) were discontinued, with nearly half of these explicitly citing COVID‐19 as their reason for discontinuation. Pharmacological trials were six times more likely to be discontinued during the pandemic than non‐pharmacological studies. The difference between the likelihood of discontinuation was statistically significant (OR: 6.13; 95% CI: 1.22–30.71). There was no evidence of association between funding source and reasons for discontinuation. Limitations, along with implications for future trials are discussed. Lay Summary We investigated the impact of the COVID‐19 pandemic on the discontinuation rate of autism clinical trials. We found that drug trials were six times more likely to be discontinued during the pandemic compared to behavioral, diagnostic, and nutritional trials. The overall discontinuation rate was notably lower in autism clinical trials than in other areas of medical research. We recommend an examination of the methodology of the continued autism trials to assess their applicability in other fields.
doi_str_mv 10.1002/aur.2764
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9348199</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2696811972</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4384-ed2a148a841aa684d670a65912a6340db05e9e2c614bd984aca29582962847f13</originalsourceid><addsrcrecordid>eNp1kVtLHDEUx0Np8Vahn6AE-uLLaG6TSXwoLFtbBUEQ7Ws4m8l2IzPJmsxY9s2P4Gf0k5j11gv4kpOQX36cnD9CnyjZp4SwAxjTPmukeIe2qOa64orI9y_7RrNNtJ3zFSGS8JptoE1ey4ZwIrbQzcXCYd8vwQ44zvH07OfJt_vbO6pxDBjGweceJ5cdJLs4xBNsU8y5ANnZwccAHYayrLLP6-etzzaGwYfRtTgmnMe8dKEtB9v54G3Bh-Shyx_Rh3kpbve57qDL70cX0-Pq9OzHyXRyWlnBlahcy4AKBUpQAKlEW9oGWWvKQHJB2hmpnXbMSipmrVYCLDBdK6YlU6KZU76Dvj55l-Osd611YUjQmWXyPaSVieDNvzfBL8yveGM0F4pqXQR7z4IUr0eXB9OXP7qug-DimA2TjSCk4bUo6Jf_0Ks4pjKdNaWlolQ37I_wcZLJzV-bocSswzQlTLMOs6Cf_27-FXxJrwDVE_Dbd271pshMLs8fhQ_r8aq3</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2696811972</pqid></control><display><type>article</type><title>The impact of COVID‐19 on autism research: A cross‐sectional analysis of discontinued or suspended clinical trials</title><source>Access via Wiley Online Library</source><creator>Neale, Monika ; Landers, Elizabeth ; Sajjadi, Nicholas B. ; Mazur‐Mosiewicz, Anya ; Hartwell, Micah</creator><creatorcontrib>Neale, Monika ; Landers, Elizabeth ; Sajjadi, Nicholas B. ; Mazur‐Mosiewicz, Anya ; Hartwell, Micah</creatorcontrib><description>Due to uncertainties associated with the COVID‐19 public health crisis, several clinical trials had to be withdrawn or postponed. Our investigation aimed to assess the rate of discontinuation of clinical trials focusing on Autism Spectrum Disorder. Of the 197 registered trials included in our systematic review, 15 (7.6%) were discontinued, with nearly half of these explicitly citing COVID‐19 as their reason for discontinuation. Pharmacological trials were six times more likely to be discontinued during the pandemic than non‐pharmacological studies. The difference between the likelihood of discontinuation was statistically significant (OR: 6.13; 95% CI: 1.22–30.71). There was no evidence of association between funding source and reasons for discontinuation. Limitations, along with implications for future trials are discussed. Lay Summary We investigated the impact of the COVID‐19 pandemic on the discontinuation rate of autism clinical trials. We found that drug trials were six times more likely to be discontinued during the pandemic compared to behavioral, diagnostic, and nutritional trials. The overall discontinuation rate was notably lower in autism clinical trials than in other areas of medical research. We recommend an examination of the methodology of the continued autism trials to assess their applicability in other fields.</description><identifier>ISSN: 1939-3792</identifier><identifier>EISSN: 1939-3806</identifier><identifier>DOI: 10.1002/aur.2764</identifier><identifier>PMID: 35670304</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley &amp; Sons, Inc</publisher><subject>Autism ; Clinical trials ; COVID-19 ; Cross-sectional studies ; discontinuation ; Medical research ; pandemic ; Pandemics ; Pharmacology ; Public health ; Short Report ; Statistical analysis ; TREATMENT</subject><ispartof>Autism research, 2022-08, Vol.15 (8), p.1560-1564</ispartof><rights>2022 International Society for Autism Research and Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4384-ed2a148a841aa684d670a65912a6340db05e9e2c614bd984aca29582962847f13</citedby><cites>FETCH-LOGICAL-c4384-ed2a148a841aa684d670a65912a6340db05e9e2c614bd984aca29582962847f13</cites><orcidid>0000-0002-0603-3271 ; 0000-0003-1716-2404</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Faur.2764$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Faur.2764$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35670304$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Neale, Monika</creatorcontrib><creatorcontrib>Landers, Elizabeth</creatorcontrib><creatorcontrib>Sajjadi, Nicholas B.</creatorcontrib><creatorcontrib>Mazur‐Mosiewicz, Anya</creatorcontrib><creatorcontrib>Hartwell, Micah</creatorcontrib><title>The impact of COVID‐19 on autism research: A cross‐sectional analysis of discontinued or suspended clinical trials</title><title>Autism research</title><addtitle>Autism Res</addtitle><description>Due to uncertainties associated with the COVID‐19 public health crisis, several clinical trials had to be withdrawn or postponed. Our investigation aimed to assess the rate of discontinuation of clinical trials focusing on Autism Spectrum Disorder. Of the 197 registered trials included in our systematic review, 15 (7.6%) were discontinued, with nearly half of these explicitly citing COVID‐19 as their reason for discontinuation. Pharmacological trials were six times more likely to be discontinued during the pandemic than non‐pharmacological studies. The difference between the likelihood of discontinuation was statistically significant (OR: 6.13; 95% CI: 1.22–30.71). There was no evidence of association between funding source and reasons for discontinuation. Limitations, along with implications for future trials are discussed. Lay Summary We investigated the impact of the COVID‐19 pandemic on the discontinuation rate of autism clinical trials. We found that drug trials were six times more likely to be discontinued during the pandemic compared to behavioral, diagnostic, and nutritional trials. The overall discontinuation rate was notably lower in autism clinical trials than in other areas of medical research. We recommend an examination of the methodology of the continued autism trials to assess their applicability in other fields.</description><subject>Autism</subject><subject>Clinical trials</subject><subject>COVID-19</subject><subject>Cross-sectional studies</subject><subject>discontinuation</subject><subject>Medical research</subject><subject>pandemic</subject><subject>Pandemics</subject><subject>Pharmacology</subject><subject>Public health</subject><subject>Short Report</subject><subject>Statistical analysis</subject><subject>TREATMENT</subject><issn>1939-3792</issn><issn>1939-3806</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kVtLHDEUx0Np8Vahn6AE-uLLaG6TSXwoLFtbBUEQ7Ws4m8l2IzPJmsxY9s2P4Gf0k5j11gv4kpOQX36cnD9CnyjZp4SwAxjTPmukeIe2qOa64orI9y_7RrNNtJ3zFSGS8JptoE1ey4ZwIrbQzcXCYd8vwQ44zvH07OfJt_vbO6pxDBjGweceJ5cdJLs4xBNsU8y5ANnZwccAHYayrLLP6-etzzaGwYfRtTgmnMe8dKEtB9v54G3Bh-Shyx_Rh3kpbve57qDL70cX0-Pq9OzHyXRyWlnBlahcy4AKBUpQAKlEW9oGWWvKQHJB2hmpnXbMSipmrVYCLDBdK6YlU6KZU76Dvj55l-Osd611YUjQmWXyPaSVieDNvzfBL8yveGM0F4pqXQR7z4IUr0eXB9OXP7qug-DimA2TjSCk4bUo6Jf_0Ks4pjKdNaWlolQ37I_wcZLJzV-bocSswzQlTLMOs6Cf_27-FXxJrwDVE_Dbd271pshMLs8fhQ_r8aq3</recordid><startdate>202208</startdate><enddate>202208</enddate><creator>Neale, Monika</creator><creator>Landers, Elizabeth</creator><creator>Sajjadi, Nicholas B.</creator><creator>Mazur‐Mosiewicz, Anya</creator><creator>Hartwell, Micah</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0603-3271</orcidid><orcidid>https://orcid.org/0000-0003-1716-2404</orcidid></search><sort><creationdate>202208</creationdate><title>The impact of COVID‐19 on autism research: A cross‐sectional analysis of discontinued or suspended clinical trials</title><author>Neale, Monika ; Landers, Elizabeth ; Sajjadi, Nicholas B. ; Mazur‐Mosiewicz, Anya ; Hartwell, Micah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4384-ed2a148a841aa684d670a65912a6340db05e9e2c614bd984aca29582962847f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Autism</topic><topic>Clinical trials</topic><topic>COVID-19</topic><topic>Cross-sectional studies</topic><topic>discontinuation</topic><topic>Medical research</topic><topic>pandemic</topic><topic>Pandemics</topic><topic>Pharmacology</topic><topic>Public health</topic><topic>Short Report</topic><topic>Statistical analysis</topic><topic>TREATMENT</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Neale, Monika</creatorcontrib><creatorcontrib>Landers, Elizabeth</creatorcontrib><creatorcontrib>Sajjadi, Nicholas B.</creatorcontrib><creatorcontrib>Mazur‐Mosiewicz, Anya</creatorcontrib><creatorcontrib>Hartwell, Micah</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Autism research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neale, Monika</au><au>Landers, Elizabeth</au><au>Sajjadi, Nicholas B.</au><au>Mazur‐Mosiewicz, Anya</au><au>Hartwell, Micah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of COVID‐19 on autism research: A cross‐sectional analysis of discontinued or suspended clinical trials</atitle><jtitle>Autism research</jtitle><addtitle>Autism Res</addtitle><date>2022-08</date><risdate>2022</risdate><volume>15</volume><issue>8</issue><spage>1560</spage><epage>1564</epage><pages>1560-1564</pages><issn>1939-3792</issn><eissn>1939-3806</eissn><abstract>Due to uncertainties associated with the COVID‐19 public health crisis, several clinical trials had to be withdrawn or postponed. Our investigation aimed to assess the rate of discontinuation of clinical trials focusing on Autism Spectrum Disorder. Of the 197 registered trials included in our systematic review, 15 (7.6%) were discontinued, with nearly half of these explicitly citing COVID‐19 as their reason for discontinuation. Pharmacological trials were six times more likely to be discontinued during the pandemic than non‐pharmacological studies. The difference between the likelihood of discontinuation was statistically significant (OR: 6.13; 95% CI: 1.22–30.71). There was no evidence of association between funding source and reasons for discontinuation. Limitations, along with implications for future trials are discussed. Lay Summary We investigated the impact of the COVID‐19 pandemic on the discontinuation rate of autism clinical trials. We found that drug trials were six times more likely to be discontinued during the pandemic compared to behavioral, diagnostic, and nutritional trials. The overall discontinuation rate was notably lower in autism clinical trials than in other areas of medical research. We recommend an examination of the methodology of the continued autism trials to assess their applicability in other fields.</abstract><cop>Hoboken, USA</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>35670304</pmid><doi>10.1002/aur.2764</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-0603-3271</orcidid><orcidid>https://orcid.org/0000-0003-1716-2404</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1939-3792
ispartof Autism research, 2022-08, Vol.15 (8), p.1560-1564
issn 1939-3792
1939-3806
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9348199
source Access via Wiley Online Library
subjects Autism
Clinical trials
COVID-19
Cross-sectional studies
discontinuation
Medical research
pandemic
Pandemics
Pharmacology
Public health
Short Report
Statistical analysis
TREATMENT
title The impact of COVID‐19 on autism research: A cross‐sectional analysis of discontinued or suspended clinical trials
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A38%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20COVID%E2%80%9019%20on%20autism%20research:%20A%20cross%E2%80%90sectional%20analysis%20of%20discontinued%20or%20suspended%20clinical%20trials&rft.jtitle=Autism%20research&rft.au=Neale,%20Monika&rft.date=2022-08&rft.volume=15&rft.issue=8&rft.spage=1560&rft.epage=1564&rft.pages=1560-1564&rft.issn=1939-3792&rft.eissn=1939-3806&rft_id=info:doi/10.1002/aur.2764&rft_dat=%3Cproquest_pubme%3E2696811972%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2696811972&rft_id=info:pmid/35670304&rfr_iscdi=true